Unknown

Dataset Information

0

Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer.


ABSTRACT: PURPOSE:Identification of suspicious PSMA-PET/CT-positive lymph node (LN) metastases (LNM) from prostate cancer (PCa) during lymphadenectomy (LA) is challenging. We evaluated an 111In-labelled PSMA ligand (DKFZ-617, referred to as [111In]PSMA-617) as a ?-emitting tracer for intraoperative ?-probe application for resected tissue samples in PCa patients. Forty-eight hours prior to LA, [111In]PSMA-617 was administered intravenously in 23 patients with suspected LNM on PSMA-PET/CT (n = 21 with biochemical relapse, n = 2 at primary therapy). Resected tissue samples (LN, LNM and fibrofatty tissue) were measured ex situ by a ?-probe expressed as counts per second (CPSnorm). [111In]PSMA-617 tissue sample uptake was measured by a germanium detector for verification and calculated as %IAlbm (percent injected activity per kilogram lean body mass at time of surgery). Based on a clinical requirement for a specificity > 95%, thresholds for both ex situ measurements were chosen accordingly. Correlation of the results from PET/CT, ?-probe and germanium detector with histopathology was done. RESULTS:Eight hundred sixty-four LNs (197 LNM) were removed from 275 subregions in 23 patients, on average 8.6 ± 14.9 LNM per patient. One hundred four of 275 tissue samples showed cancer. Median ?-probe and germanium detector results were significantly different between tumour-affected (33.5 CPSnorm, 0.71 %IAlbm) and tumour-free subregions (3.0 CPSnorm, 0.03 %IAlbm) (each p value < 0.0001). For the chosen ?-probe cut-off (CPSnorm > 23) and germanium detector cut-off (%IAlbm > 0.27), 64 and 74 true-positive and 158 true-negative samples for both measurements were identified. Thirty-nine and 30 false-negative and 6 and 5 false-positive tissue samples were identified by ?-probe and germanium detector measurements. CONCLUSION:[111In]PSMA-617 application for LA is feasible in terms of an intraoperative real-time measurement with a ?-probe for detection of tumour-affected tissue samples. ?-probe results can be confirmed by precise germanium detector measurements and were significantly different between tumour-affected and tumour-free samples.

SUBMITTER: Jilg CA 

PROVIDER: S-EPMC7060305 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Results from extended lymphadenectomies with [<sup>111</sup>In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer.

Jilg Cordula A CA   Reichel Kathrin K   Stoykow Christian C   Rischke H Christian HC   Bartholomä Mark M   Drendel Vanessa V   von Büren Moritz M   Schultze-Seemann Wolfgang W   Meyer Philipp T PT   Mix Michael M  

EJNMMI research 20200306 1


<h4>Purpose</h4>Identification of suspicious PSMA-PET/CT-positive lymph node (LN) metastases (LNM) from prostate cancer (PCa) during lymphadenectomy (LA) is challenging. We evaluated an <sup>111</sup>In-labelled PSMA ligand (DKFZ-617, referred to as [<sup>111</sup>In]PSMA-617) as a γ-emitting tracer for intraoperative γ-probe application for resected tissue samples in PCa patients. Forty-eight hours prior to LA, [<sup>111</sup>In]PSMA-617 was administered intravenously in 23 patients with suspec  ...[more]

Similar Datasets

| S-EPMC6704039 | biostudies-literature
| S-EPMC6882876 | biostudies-literature
| S-EPMC8688644 | biostudies-literature